Claims for Patent: 8,748,577

Summary for Patent: 8,748,577

Title:	Conjugates of biologically active polypeptides having an increased in vivo half-life
Abstract:	Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
Inventor(s):	Besman; Marc (Seattle, WA), Chipman; Stewart (Bainbridge Island, WA), Leung; David (Mercer Island, WA), Singer; Jack (Seattle, WA)
Assignee:	Cell Therapeutics, Inc. (Seattle, WA)
Application Number:	13/363,278
Patent Claims:	1. A biologically active protein conjugate comprising a biologically active polypeptide coupled via a peptide bond to an amino acid extension comprising from 2 to 75 repeating units of a peptide motif, wherein said peptide motif consists of two residues Asn (N) and one residue of an amino acid selected from the group consisting of Ser (S) and Thr (T), wherein the biologically active polypeptide is human growth hormone SEQ ID NO:2472, granulocyte macrophage colony stimulating factor (GM-CSF; SEQ ID NO:2462), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF; SEQ ID NOs:2454, 2456, 2458, or 2460), colony stimulating factor (CSF), platelet derived growth factor (PDGF), tumor necrosis factor (TNF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor, (FGF), nerve growth factor (NGF), erythropoietin (EPO; SEQ ID NOs:2452, 2480, or 2481), interferon, interferon gamma inducing factor I (IGIF), transforming growth factor beta (TGF-.beta.), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory protein-1-alpha (MIP-1-.alpha.), macrophage inflammatory protein-1-.beta. (MIP-1-.beta.), Leishmania elongation initiating factor (LEIF), brain derived neurotrophic factor (BDNF), neurotrophin-2 (NT-2), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5 (NT-5), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), a soluble tumor necrosis factor (TNF) type II receptor, a soluble tumor necrosis factor (TNF) type I receptor, a soluble IL-1 receptor type II, a soluble IL-4 receptor, a soluble gp120 glycoprotein, a soluble gp160 glycoprotein, an IL-1 receptor antagonist, a coagulation factor, insulin, activated protein C, Factor VII, collagenase, agalsidase-beta, dornase-alpha, alteplase, pegylated-asparaginase, asparaginase, or imiglucerase, and wherein said biologically active protein conjugate has an increased plasma half-life compared to the plasma half-life of the unmodified biologically active polypeptide. 2. The biologically active protein conjugate of claim 1, wherein said peptide motif has an amino acid sequence selected from the group consisting of SNN, NSN, NNS, TNN, NTN, and NNT. 3. The biologically active protein conjugate of claim 1, wherein said amino acid extension is situated at the N-terminus with respect to said biologically active polypeptide, is situated at the C-terminus with respect to said biologically active polypeptide, or is situated at both the N- and C-termini with respect to said biologically active polypeptide. 4. The biologically active protein conjugate of claim 1, wherein said interferon is selected from the group consisting of a beta-interferon (SEQ ID NO:2468) and a gamma-interferon (SEQ ID NO:2470). 5. The biologically active protein conjugate of claim 1, wherein said biologically protein conjugate further comprises a leader sequence. 6. The biologically active protein conjugate of claim 5, wherein the leader sequence is the Schizosaccharomyces pome acid phosphatase (PHO) leader sequence (amino acid residues 1 to 18 of SEQ ID NO:2450). 7. The biologically active protein conjugate of claim 1, wherein said biologically active protein conjugate further comprises a linker. 8. A composition comprising the biologically active protein conjugate of claim 1 and a pharmaceutically effective carrier.

Details for Patent 8,748,577

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	05/23/1994		2025-01-25
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	09/22/1999		2025-01-25
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-01-25
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2025-01-25
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2025-01-25
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2025-01-25
Genzyme Corporation	FABRAZYME	agalsidase beta	For Injection	103979	04/24/2003		2025-01-25